09:29 AM EDT, 05/28/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday it has signed a clinical supply agreement with BeiGene ( BGNE ) to evaluate the safety and efficacy of its Bria-OTS immunotherapy, in combination with BeiGene's ( BGNE ) tislelizumab anti-PD-1 antibody, for the treatment of advanced heavily pretreated metastatic breast cancer.

The upcoming phase 1/2 clinical trial will initially evaluate the safety and efficacy of Bria-OTS alone in treating breast cancer and later in combination with tislelizumab.

BriaCell also plans to evaluate Bria-OTS in prostate and other cancers, the company said. The companies declined to provide additional information.

Price: 1.3800, Change: -0.05, Percent Change: -3.50